

BRISTOL MYERS SQUIBB CO  
Form 8-K  
April 16, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act Of 1934**

**Date of Report (Date of earliest event reported): April 16, 2015**

**BRISTOL-MYERS SQUIBB COMPANY**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**1-1136**  
**(Commission**

**File Number)**  
**345 Park Avenue**

**22-0790350**  
**(IRS Employer**

**Identification Number)**

**New York, NY, 10154**

**(Address of Principal Executive Office)**

**Registrant's telephone number, including area code: (212) 546-4000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- “ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On April 16, 2015, Bristol-Myers Squibb Company (the Company) and Eli Lilly and Company (Lilly) issued a joint press release announcing that the companies have agreed to transfer all rights of Erbitux (cetuximab) in North America from the Company to Lilly. The transaction is expected to result in a non-cash pre-tax charge of approximately \$150 million to \$200 million during 2015, which will be a specified item. Royalties are expected to be accounted for as other income. The transaction is not expected to have a significant impact on our non-GAAP earnings. A copy of the press release announcing the transaction is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 Press release of Bristol-Myers Squibb Company dated April 16, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRISTOL-MYERS SQUIBB COMPANY

Dated: April 16, 2015

By: /s/ Sandra Leung  
Name: Sandra Leung  
Title: General Counsel and Corporate Secretary

**EXHIBIT INDEX**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press release of Bristol-Myers Squibb Company dated April 16, 2015.